[{"id":"babb040a-8e58-46a5-a8a3-a326e81d8c49","acronym":"MORAb-202-G000-201","url":"https://clinicaltrials.gov/study/NCT04300556","created_at":"2021-01-18T20:51:39.021Z","updated_at":"2025-02-25T14:29:08.502Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","source_id_and_acronym":"NCT04300556 - MORAb-202-G000-201","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • BRAF • ER • ALK • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRAF • ER • ALK • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003) • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 08/06/2020","start_date":" 08/06/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-12-09"},{"id":"cd892406-57e9-4ba5-95af-1d838d031b7c","acronym":"CA116-001","url":"https://clinicaltrials.gov/study/NCT05613088","created_at":"2023-12-07T21:16:29.597Z","updated_at":"2025-02-25T13:36:17.948Z","phase":"Phase 2","brief_title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT05613088 - CA116-001","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/05/2024","primary_completion_date":" 06/05/2024","study_txt":" Completion: 10/11/2026","study_completion_date":" 10/11/2026","last_update_posted":"2024-11-21"},{"id":"bada2cec-2867-4ca7-af44-a78f58534df5","acronym":"MORAb-202-J081-101","url":"https://clinicaltrials.gov/study/NCT03386942","created_at":"2021-01-18T16:42:54.664Z","updated_at":"2024-07-02T16:35:59.940Z","phase":"Phase 1","brief_title":"A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors","source_id_and_acronym":"NCT03386942 - MORAb-202-J081-101","lead_sponsor":"Eisai Inc.","biomarkers":" BRAF • ALK","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 10/26/2022","primary_completion_date":" 10/26/2022","study_txt":" Completion: 10/26/2022","study_completion_date":" 10/26/2022","last_update_posted":"2022-11-28"}]